# Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 29.2 | 68.4 | (41.8-105.7) |  | Male | 18 | 18.8 | 95.5 | (56.6-151.0) |
| Female | 8 | 10.7 | 74.8 | (32.2-147.4) |  | Female | 12 | 14.7 | 81.6 | (42.1-142.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 5.4 | nc | (nc-nc) |  | Male | 7 | 6.0 | 116.5 | (46.7-240.0) |
| Female | 6 | 4.7 | 126.3 | (46.1-275.0) |  | Female | 1 | 5.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 15 | 16.6 | 90.4 | (50.5-149.1) |
| Female | 129 | 119.4 | 108.1 | (90.2-128.4) |  | Female | 11 | 14.7 | 74.6 | (37.2-133.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 14.4 | 62.4 | (28.5-118.4) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 6 | 6.5 | 93.0 | (34.0-202.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 36 | 31.2 | 115.6 | (80.9-160.0) |  |  |  |  |  |  |
| Female | 31 | 31.0 | 100.1 | (68.0-142.0) |  | Female | 15 | 10.2 | 146.5 | (81.9-241.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 7.5 | nc | (nc-nc) |  | Male | 13 | 10.9 | 118.8 | (63.2-203.1) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 11 | 11.2 | 98.2 | (48.9-175.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 114 | 91.1 | 125.1 | (103.2-150.3) |
| Female | 3 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 17.2 | 98.8 | (57.5-158.2) |  | Male | 8 | 6.9 | 115.7 | (49.8-228.0) |
| Female | 8 | 9.5 | 84.5 | (36.4-166.5) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  | Male | 6 | 3.6 | 166.3 | (60.7-362.0) |
| Female | 2 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 9 | 11.6 | 77.4 | (35.3-147.0) |  | Male | 4 | 7.6 | nc | (nc-nc) |
| Female | 8 | 8.6 | 93.1 | (40.1-183.4) |  | Female | 24 | 21.2 | 113.2 | (72.5-168.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 9 | 10.6 | 84.6 | (38.6-160.6) |  |  |  |  |  |  |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 21 | 26.8 | 78.4 | (48.5-119.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 53 | 50.8 | 104.4 | (78.2-136.5) |  | Male | 389 | 376.4 | 103.4 | (93.3-114.2) |
| Female | 50 | 55.4 | 90.2 | (67.0-119.0) |  | Female | 386 | 398.4 | 96.9 | (87.5-107.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

316

# Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 56 | 57.7 | 97.0 | (73.3-126.0) |  | Male | 19 | 37.0 | 51.4 | (30.9-80.3) |
| Female | 23 | 21.4 | 107.5 | (68.2-161.4) |  | Female | 16 | 29.5 | 54.3 | (31.0-88.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 16 | 11.6 | 137.7 | (78.7-223.7) |  | Male | 9 | 11.6 | 77.6 | (35.4-147.3) |
| Female | 13 | 10.1 | 128.2 | (68.2-219.2) |  | Female | 6 | 9.8 | 61.3 | (22.4-133.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 2.0 | nc | (nc-nc) |  | Male | 28 | 33.0 | 84.8 | (56.3-122.5) |
| Female | 251 | 223.0 | 112.6 | (99.1-127.4) |  | Female | 30 | 29.0 | 103.5 | (69.8-147.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 26.3 | 60.8 | (34.7-98.8) |
| Female | 10 | 7.4 | 134.8 | (64.6-248.0) |  | Female | 9 | 12.7 | 70.8 | (32.3-134.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 67 | 59.2 | 113.1 | (87.6-143.6) |  |  |  |  |  |  |
| Female | 65 | 60.7 | 107.1 | (82.7-136.5) |  | Female | 21 | 19.9 | 105.4 | (65.2-161.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 14.2 | 63.3 | (28.9-120.2) |  | Male | 29 | 21.0 | 138.1 | (92.5-198.3) |
| Female | 6 | 4.1 | 145.2 | (53.0-316.1) |  | Female | 23 | 22.5 | 102.4 | (64.9-153.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 5.5 | 108.6 | (39.6-236.3) |  | Male | 141 | 166.9 | 84.5 | (71.1-99.6) |
| Female | 5 | 4.8 | 104.3 | (33.6-243.4) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 32.2 | 111.7 | (78.2-154.6) |  | Male | 17 | 13.4 | 127.0 | (74.0-203.4) |
| Female | 23 | 18.4 | 125.2 | (79.3-187.8) |  | Female | 13 | 8.6 | 151.4 | (80.5-258.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 8.2 | 73.0 | (26.7-158.9) |  | Male | 12 | 11.0 | 109.4 | (56.5-191.1) |
| Female | 3 | 2.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 20 | 23.9 | 83.6 | (51.1-129.2) |  | Male | 23 | 15.5 | 148.6 | (94.2-223.1) |
| Female | 16 | 17.9 | 89.4 | (51.1-145.2) |  | Female | 44 | 43.8 | 100.4 | (72.9-134.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 22 | 19.7 | 111.9 | (70.1-169.4) |  |  |  |  |  |  |
| Female | 4 | 7.1 | nc | (nc-nc) |  | Female | 44 | 51.0 | 86.3 | (62.7-115.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 106 | 99.9 | 106.1 | (86.8-128.3) |  | Male | 690 | 729.3 | 94.6 | (87.7-101.9) |
| Female | 102 | 109.1 | 93.5 | (76.2-113.5) |  | Female | 774 | 778.4 | 99.4 | (92.6-106.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

317

# Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 11 | 11.2 | 98.2 | (48.9-175.7) |  | Male | 4 | 7.2 | nc | (nc-nc) |
| Female | 1 | 3.8 | nc | (nc-nc) |  | Female | 5 | 5.4 | 93.2 | (30.0-217.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 7 | 6.4 | 109.0 | (43.7-224.7) |
| Female | 39 | 45.0 | 86.6 | (61.6-118.3) |  | Female | 7 | 5.3 | 133.3 | (53.4-274.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.6 | nc | (nc-nc) |
| Female | 0 | 1.4 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 14 | 11.9 | 118.1 | (64.5-198.2) |  |  |  |  |  |  |
| Female | 11 | 10.7 | 103.1 | (51.4-184.5) |  | Female | 4 | 3.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 8 | 4.2 | 189.4 | (81.5-373.2) |
| Female | 1 | 0.8 | nc | (nc-nc) |  | Female | 7 | 3.9 | 177.7 | (71.2-366.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 24 | 36.7 | 65.5 | (41.9-97.4) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 6.7 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 6 | 3.6 | 169.0 | (61.7-367.8) |  | Female | 3 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.7 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 4.5 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 3 | 3.0 | nc | (nc-nc) |  | Female | 4 | 8.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 4.1 | 120.6 | (38.9-281.5) |  |  |  |  |  |  |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 12 | 10.5 | 114.4 | (59.1-199.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 23 | 19.8 | 116.1 | (73.6-174.2) |  | Male | 134 | 146.8 | 91.3 | (76.5-108.1) |
| Female | 20 | 20.8 | 96.2 | (58.7-148.6) |  | Female | 141 | 147.1 | 95.8 | (80.7-113.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

318

# Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 39 | 29.4 | 132.6 | (94.3-181.3) |  | Male | 14 | 18.2 | 76.8 | (41.9-128.8) |
| Female | 21 | 9.6 | 218.4 | (135.2-333.9) |  | Female | 13 | 13.2 | 98.6 | (52.4-168.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 10 | 5.1 | 196.8 | (94.2-361.9) |  | Male | 8 | 5.9 | 135.7 | (58.4-267.4) |
| Female | 1 | 4.3 | nc | (nc-nc) |  | Female | 4 | 4.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 18 | 16.1 | 112.1 | (66.4-177.1) |
| Female | 94 | 109.3 | 86.0 | (69.5-105.3) |  | Female | 8 | 13.2 | 60.5 | (26.0-119.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 13.0 | 115.6 | (64.7-190.7) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 9 | 5.9 | 152.6 | (69.6-289.7) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 33 | 29.6 | 111.4 | (76.7-156.5) |  |  |  |  |  |  |
| Female | 36 | 26.8 | 134.1 | (93.9-185.7) |  | Female | 7 | 9.4 | 74.7 | (29.9-153.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 7.1 | 126.0 | (57.5-239.1) |  | Male | 17 | 10.6 | 159.8 | (93.0-255.9) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 17 | 9.9 | 172.2 | (100.3-275.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 88 | 83.3 | 105.7 | (84.8-130.2) |
| Female | 2 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 13 | 15.9 | 81.6 | (43.4-139.5) |  | Male | 3 | 6.7 | nc | (nc-nc) |
| Female | 15 | 8.8 | 170.9 | (95.6-281.9) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  | Male | 5 | 3.1 | 160.7 | (51.8-375.1) |
| Female | 2 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 15 | 11.3 | 133.0 | (74.4-219.4) |  | Male | 7 | 6.6 | 106.6 | (42.7-219.6) |
| Female | 15 | 7.7 | 195.9 | (109.6-323.1) |  | Female | 20 | 19.3 | 103.6 | (63.3-160.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 15 | 9.8 | 152.7 | (85.4-251.9) |  |  |  |  |  |  |
| Female | 5 | 3.3 | 152.3 | (49.1-355.5) |  | Female | 24 | 25.4 | 94.5 | (60.5-140.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 71 | 51.7 | 137.4 | (107.3-173.3) |  | Male | 418 | 359.4 | 116.3 | (105.4-128.0) |
| Female | 74 | 51.8 | 143.0 | (112.2-179.5) |  | Female | 408 | 362.4 | 112.6 | (101.9-124.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

319

# Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 5 | 5.1 | 98.2 | (31.6-229.1) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 15 | 21.8 | 68.7 | (38.4-113.4) |  | Female | 2 | 2.6 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 5.7 | 140.9 | (60.7-277.6) |  |  |  |  |  |  |
| Female | 6 | 5.5 | 110.0 | (40.2-239.5) |  | Female | 0 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 1.4 | nc | (nc-nc) |  | Male | 4 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 13 | 17.9 | 72.5 | (38.6-123.9) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 3.3 | nc | (nc-nc) |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 3 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.1 | nc | (nc-nc) |  | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 3 | 4.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 7 | 4.7 | 150.0 | (60.1-309.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 9.2 | 87.1 | (37.5-171.7) |  | Male | 64 | 70.4 | 90.9 | (70.0-116.1) |
| Female | 9 | 9.7 | 92.5 | (42.2-175.5) |  | Female | 53 | 71.6 | 74.1 | (55.5-96.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

320

# Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.4 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 3 | 4.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 5 | 4.1 | 120.6 | (38.9-281.5) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 2.5 | nc | (nc-nc) |  | Male | 13 | 17.1 | 76.1 | (40.5-130.1) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 14 | 14.4 | 97.0 | (53.0-162.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

321

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 1.7 | nc | (nc-nc) |  | Male | 5 | 12.7 | 39.5 | (12.7-92.2) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 9 | 9.9 | 91.3 | (41.7-173.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

322

# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 29 | 29.4 | 98.5 | (66.0-141.5) |  | Male | 12 | 19.7 | 61.0 | (31.5-106.6) |
| Female | 8 | 12.7 | 62.9 | (27.1-123.9) |  | Female | 21 | 18.2 | 115.6 | (71.6-176.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 6.3 | 95.9 | (35.0-208.8) |  | Male | 8 | 6.2 | 129.4 | (55.7-255.0) |
| Female | 7 | 5.9 | 118.7 | (47.6-244.7) |  | Female | 5 | 6.0 | 83.9 | (27.0-195.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.1 | nc | (nc-nc) |  | Male | 13 | 17.6 | 74.0 | (39.3-126.5) |
| Female | 160 | 140.5 | 113.8 | (96.9-132.9) |  | Female | 16 | 17.6 | 90.9 | (51.9-147.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 14.8 | 81.3 | (41.9-142.0) |
| Female | 9 | 4.7 | 192.8 | (88.0-366.0) |  | Female | 13 | 7.8 | 166.8 | (88.7-285.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 42 | 32.2 | 130.4 | (94.0-176.3) |  |  |  |  |  |  |
| Female | 33 | 35.5 | 92.8 | (63.9-130.4) |  | Female | 17 | 12.3 | 138.6 | (80.7-221.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 7.6 | 92.7 | (37.1-191.0) |  | Male | 13 | 11.0 | 117.7 | (62.6-201.4) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 17 | 13.3 | 128.1 | (74.6-205.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 72 | 90.7 | 79.4 | (62.1-100.0) |
| Female | 2 | 2.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 14 | 18.0 | 78.0 | (42.6-130.8) |  | Male | 10 | 7.1 | 141.7 | (67.8-260.5) |
| Female | 3 | 11.4 | nc | (nc-nc) |  | Female | 8 | 5.0 | 158.9 | (68.4-313.2) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 7 | 4.4 | 157.7 | (63.2-324.9) |  | Male | 5 | 5.9 | 84.8 | (27.3-198.0) |
| Female | 0 | 1.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 17 | 12.5 | 135.7 | (79.0-217.2) |  | Male | 9 | 8.8 | 102.3 | (46.7-194.2) |
| Female | 13 | 10.3 | 125.8 | (66.9-215.1) |  | Female | 35 | 27.5 | 127.2 | (88.6-177.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 10.8 | 55.5 | (20.3-120.9) |  |  |  |  |  |  |
| Female | 5 | 4.2 | 118.4 | (38.2-276.3) |  | Female | 27 | 32.9 | 82.1 | (54.1-119.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 52 | 51.5 | 100.9 | (75.4-132.4) |  | Male | 373 | 389.1 | 95.9 | (86.4-106.1) |
| Female | 60 | 67.7 | 88.7 | (67.7-114.1) |  | Female | 499 | 478.1 | 104.4 | (95.4-113.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

323

# Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 17.9 | 95.1 | (55.4-152.3) |  | Male | 23 | 11.3 | 204.1 | (129.4-306.3) |
| Female | 6 | 6.4 | 93.4 | (34.1-203.2) |  | Female | 12 | 8.6 | 139.6 | (72.1-243.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.1 | nc | (nc-nc) |  | Male | 4 | 3.7 | nc | (nc-nc) |
| Female | 4 | 2.7 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 8 | 9.9 | 80.9 | (34.9-159.5) |
| Female | 77 | 72.5 | 106.2 | (83.8-132.7) |  | Female | 12 | 8.7 | 137.3 | (70.9-239.9) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 8.2 | 60.8 | (19.6-141.8) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 13 | 18.5 | 70.3 | (37.4-120.2) |  |  |  |  |  |  |
| Female | 11 | 18.0 | 61.2 | (30.5-109.4) |  | Female | 4 | 6.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 4.5 | nc | (nc-nc) |  | Male | 5 | 6.6 | 76.2 | (24.5-177.7) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 8 | 6.6 | 121.5 | (52.3-239.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 65 | 51.9 | 125.3 | (96.7-159.7) |
| Female | 2 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 10.1 | 69.6 | (27.9-143.3) |  | Male | 2 | 4.2 | nc | (nc-nc) |
| Female | 2 | 5.8 | nc | (nc-nc) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 6 | 6.9 | 86.9 | (31.7-189.2) |  | Male | 6 | 4.2 | 141.7 | (51.8-308.5) |
| Female | 3 | 4.9 | nc | (nc-nc) |  | Female | 12 | 12.2 | 98.5 | (50.8-172.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 6.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 13 | 16.6 | 78.4 | (41.7-134.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 31.4 | 51.0 | (29.1-82.8) |  | Male | 203 | 221.9 | 91.5 | (79.3-105.0) |
| Female | 19 | 34.6 | 54.9 | (33.0-85.8) |  | Female | 210 | 239.0 | 87.9 | (76.4-100.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

324

# Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 25 | 21.3 | 117.4 | (76.0-173.3) |  | Male | 12 | 13.0 | 92.6 | (47.8-161.8) |
| Female | 5 | 7.2 | 69.0 | (22.2-161.0) |  | Female | 8 | 9.8 | 81.6 | (35.2-160.9) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.6 | nc | (nc-nc) |  | Male | 4 | 4.2 | nc | (nc-nc) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 6 | 3.3 | 180.9 | (66.1-393.7) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 13 | 11.4 | 113.8 | (60.5-194.6) |
| Female | 81 | 76.3 | 106.2 | (84.3-132.0) |  | Female | 11 | 9.7 | 113.0 | (56.3-202.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 16 | 9.2 | 174.3 | (99.5-283.0) |
| Female | 4 | 2.6 | nc | (nc-nc) |  | Female | 5 | 4.3 | 117.5 | (37.9-274.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 20 | 21.5 | 93.0 | (56.8-143.6) |  |  |  |  |  |  |
| Female | 19 | 20.9 | 90.8 | (54.6-141.8) |  | Female | 14 | 6.7 | 208.6 | (113.9-350.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 7 | 5.1 | 136.7 | (54.8-281.7) |  | Male | 8 | 7.6 | 105.2 | (45.3-207.3) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 10 | 7.6 | 131.2 | (62.8-241.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 58 | 59.1 | 98.2 | (74.6-127.0) |
| Female | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 11.2 | 97.9 | (48.8-175.1) |  | Male | 2 | 4.8 | nc | (nc-nc) |
| Female | 10 | 6.2 | 160.5 | (76.8-295.1) |  | Female | 2 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 6 | 2.9 | 205.3 | (75.0-447.0) |  | Male | 3 | 2.3 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.1 | 86.3 | (34.6-177.8) |  | Male | 5 | 4.7 | 107.0 | (34.5-249.8) |
| Female | 6 | 5.9 | 101.5 | (37.1-221.0) |  | Female | 16 | 14.3 | 111.7 | (63.8-181.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 6.9 | 145.0 | (69.4-266.6) |  |  |  |  |  |  |
| Female | 5 | 2.4 | 212.0 | (68.3-494.9) |  | Female | 22 | 16.8 | 130.6 | (81.8-197.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 49 | 36.3 | 134.9 | (99.8-178.3) |  | Male | 292 | 256.2 | 114.0 | (101.3-127.8) |
| Female | 59 | 36.9 | 159.8 | (121.7-206.2) |  | Female | 321 | 262.6 | 122.3 | (109.2-136.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

325

# Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 30.2 | 62.9 | (37.8-98.2) |  | Male | 35 | 19.0 | 183.8 | (128.0-255.6) |
| Female | 8 | 9.9 | 80.6 | (34.7-158.8) |  | Female | 26 | 14.3 | 181.8 | (118.7-266.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 5.5 | nc | (nc-nc) |  | Male | 6 | 6.2 | 96.8 | (35.3-210.7) |
| Female | 7 | 5.1 | 136.1 | (54.5-280.5) |  | Female | 7 | 4.7 | 150.5 | (60.3-310.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 15 | 16.9 | 88.6 | (49.6-146.2) |
| Female | 147 | 117.4 | 125.2 | (105.8-147.2) |  | Female | 7 | 14.0 | 50.0 | (20.0-103.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 10 | 14.0 | 71.7 | (34.3-131.8) |
| Female | 3 | 4.0 | nc | (nc-nc) |  | Female | 5 | 6.2 | 80.8 | (26.0-188.5) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 31.3 | 73.4 | (46.5-110.2) |  |  |  |  |  |  |
| Female | 24 | 29.2 | 82.3 | (52.7-122.4) |  | Female | 11 | 9.9 | 110.6 | (55.1-198.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 7.5 | nc | (nc-nc) |  | Male | 8 | 11.1 | 72.1 | (31.0-142.1) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 9 | 10.3 | 87.3 | (39.8-165.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.8 | nc | (nc-nc) |  | Male | 113 | 88.4 | 127.9 | (105.4-153.7) |
| Female | 3 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 17.2 | 87.4 | (48.9-144.2) |  | Male | 7 | 7.0 | 99.5 | (39.8-204.9) |
| Female | 5 | 9.2 | 54.5 | (17.6-127.1) |  | Female | 2 | 4.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 4.4 | nc | (nc-nc) |  | Male | 3 | 3.2 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 12.0 | 99.9 | (51.5-174.4) |  | Male | 7 | 7.4 | 95.0 | (38.1-195.7) |
| Female | 9 | 8.4 | 106.5 | (48.6-202.3) |  | Female | 21 | 22.4 | 93.8 | (58.0-143.3) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 10.3 | 58.2 | (21.3-126.7) |  |  |  |  |  |  |
| Female | 1 | 3.3 | nc | (nc-nc) |  | Female | 26 | 25.4 | 102.5 | (66.9-150.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 52.5 | 34.3 | (20.3-54.2) |  | Male | 322 | 377.5 | 85.3 | (76.2-95.2) |
| Female | 35 | 52.0 | 67.3 | (46.9-93.6) |  | Female | 387 | 385.6 | 100.4 | (90.6-110.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

326

# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 4 | 6.2 | nc | (nc-nc) |  | Male | 5 | 3.6 | 138.6 | (44.7-323.5) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 0 | 1.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 7 | 3.1 | 223.8 | (89.7-461.1) |
| Female | 22 | 25.8 | 85.4 | (53.5-129.3) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 7 | 5.8 | 121.1 | (48.5-249.6) |  |  |  |  |  |  |
| Female | 4 | 7.1 | nc | (nc-nc) |  | Female | 3 | 2.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 0 | 2.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 5 | 2.9 | 173.6 | (55.9-405.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 15 | 19.0 | 78.8 | (44.1-130.0) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) |  | Female | 1 | 3.2 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 4 | 6.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 11.3 | nc | (nc-nc) |  | Male | 63 | 74.5 | 84.5 | (64.9-108.1) |
| Female | 10 | 14.8 | 67.7 | (32.4-124.4) |  | Female | 71 | 90.5 | 78.5 | (61.3-99.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

327

# Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 2 | 4.9 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 2 | 4.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 2 | 0.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.2 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 14 | 16.8 | 83.5 | (45.6-140.1) |
| Female | 3 | 2.1 | nc | (nc-nc) |  | Female | 11 | 15.1 | 73.0 | (36.4-130.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

328

# Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 6 | 5.8 | 103.9 | (38.0-226.3) |  | Male | 6 | 3.4 | 176.0 | (64.3-383.1) |
| Female | 1 | 2.0 | nc | (nc-nc) |  | Female | 7 | 2.6 | 272.2 | (109.0-560.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 3.1 | 162.4 | (52.3-379.0) |
| Female | 27 | 20.7 | 130.5 | (86.0-189.9) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 8 | 5.7 | 139.2 | (59.9-274.2) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 1.3 | nc | (nc-nc) |  | Male | 2 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 20 | 14.0 | 142.9 | (87.3-220.7) |
| Female | 1 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 2 | 2.8 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 4 | 3.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 6 | 4.6 | 131.3 | (48.0-285.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 3 | 9.8 | nc | (nc-nc) |  | Male | 66 | 65.8 | 100.3 | (77.6-127.6) |
| Female | 11 | 10.1 | 109.2 | (54.4-195.3) |  | Female | 83 | 71.2 | 116.6 | (92.9-144.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

329

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 9.0 | 187.9 | (109.4-300.8) |  | Male | 8 | 5.9 | 134.6 | (58.0-265.3) |
| Female | 5 | 3.1 | 159.6 | (51.4-372.4) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 2 | 1.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 3 | 5.3 | nc | (nc-nc) |
| Female | 23 | 29.8 | 77.1 | (48.9-115.7) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 5 | 4.4 | 113.4 | (36.6-264.7) |
| Female | 1 | 0.9 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 5 | 9.5 | 52.8 | (17.0-123.3) |  |  |  |  |  |  |
| Female | 7 | 8.8 | 79.9 | (32.0-164.7) |  | Female | 5 | 2.7 | 187.2 | (60.3-436.9) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.3 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 3.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.0 | nc | (nc-nc) |  | Male | 28 | 28.2 | 99.3 | (66.0-143.5) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 5.3 | 168.3 | (76.8-319.5) |  | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 1 | 1.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.8 | nc | (nc-nc) |  | Male | 1 | 2.6 | nc | (nc-nc) |
| Female | 4 | 2.4 | nc | (nc-nc) |  | Female | 9 | 4.7 | 191.8 | (87.5-364.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 5 | 6.8 | 73.4 | (23.7-171.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 15.9 | 157.1 | (101.6-231.9) |  | Male | 136 | 118.7 | 114.6 | (96.1-135.5) |
| Female | 13 | 15.8 | 82.4 | (43.9-141.0) |  | Female | 108 | 105.6 | 102.2 | (83.9-123.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

330

# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 10 | 9.6 | 104.0 | (49.8-191.2) |  | Male | 10 | 5.9 | 170.8 | (81.8-314.2) |
| Female | 3 | 2.7 | nc | (nc-nc) |  | Female | 3 | 3.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 9 | 5.2 | 172.5 | (78.7-327.5) |
| Female | 38 | 31.5 | 120.6 | (85.4-165.6) |  | Female | 8 | 3.8 | 211.2 | (90.9-416.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 4.2 | 167.3 | (67.0-344.8) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 8 | 9.7 | 82.3 | (35.4-162.2) |  |  |  |  |  |  |
| Female | 17 | 7.9 | 215.2 | (125.3-344.5) |  | Female | 2 | 2.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.3 | nc | (nc-nc) |  | Male | 1 | 3.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 21 | 27.3 | 76.9 | (47.6-117.6) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 5.1 | 97.9 | (31.5-228.4) |  | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 3 | 2.5 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 1.3 | nc | (nc-nc) |  | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 3.7 | nc | (nc-nc) |  | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 11 | 5.7 | 192.7 | (96.1-344.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 5 | 7.2 | 69.2 | (22.3-161.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 16.4 | 110.1 | (65.2-174.0) |  | Male | 117 | 116.6 | 100.3 | (83.0-120.3) |
| Female | 16 | 14.1 | 113.1 | (64.6-183.7) |  | Female | 124 | 104.1 | 119.1 | (99.1-142.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

331

# West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 5.3 | nc | (nc-nc) |  | Male | 5 | 3.3 | 152.7 | (49.2-356.4) |
| Female | 0 | 2.1 | nc | (nc-nc) |  | Female | 1 | 2.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 3 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 16 | 19.2 | 83.2 | (47.5-135.2) |  | Female | 3 | 2.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 3 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 5.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 5.8 | nc | (nc-nc) |  | Female | 4 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) |  | Female | 2 | 2.2 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 11 | 16.2 | 68.1 | (33.9-121.8) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 2.9 | 169.6 | (54.6-395.7) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 6 | 4.4 | 134.9 | (49.3-293.6) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 9 | 9.2 | 97.4 | (44.5-185.0) |  | Male | 50 | 66.1 | 75.7 | (56.2-99.8) |
| Female | 13 | 10.3 | 126.1 | (67.1-215.6) |  | Female | 61 | 69.0 | 88.4 | (67.6-113.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

332

# West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 5.3 | 149.8 | (64.5-295.1) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 0 | 1.6 | nc | (nc-nc) |  | Female | 3 | 2.4 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 1.0 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 2 | 3.0 | nc | (nc-nc) |
| Female | 22 | 20.2 | 108.7 | (68.1-164.6) |  | Female | 0 | 2.3 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 5.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 4.7 | nc | (nc-nc) |  | Female | 2 | 1.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 1.4 | nc | (nc-nc) |  | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 23 | 17.4 | 132.4 | (83.9-198.7) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 7 | 3.2 | 219.2 | (87.8-451.6) |  | Male | 2 | 1.3 | nc | (nc-nc) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 3 | 3.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 4 | 4.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 9.3 | nc | (nc-nc) |  | Male | 66 | 69.7 | 94.7 | (73.2-120.5) |
| Female | 4 | 8.4 | nc | (nc-nc) |  | Female | 50 | 64.4 | 77.7 | (57.6-102.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

333

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 35 | 29.4 | 118.9 | (82.8-165.4) |  | Male | 14 | 19.0 | 73.9 | (40.4-124.0) |
| Female | 11 | 11.5 | 95.5 | (47.6-170.8) |  | Female | 9 | 15.9 | 56.5 | (25.8-107.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 5.8 | 120.5 | (48.3-248.3) |  | Male | 2 | 6.1 | nc | (nc-nc) |
| Female | 9 | 5.2 | 172.9 | (78.9-328.2) |  | Female | 4 | 5.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 1.0 | nc | (nc-nc) |  | Male | 18 | 17.0 | 106.1 | (62.9-167.8) |
| Female | 117 | 127.4 | 91.8 | (75.9-110.0) |  | Female | 16 | 15.7 | 102.1 | (58.3-165.8) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 18 | 14.3 | 125.5 | (74.3-198.3) |
| Female | 8 | 4.1 | 193.1 | (83.2-380.6) |  | Female | 7 | 7.0 | 100.4 | (40.2-207.0) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 52 | 30.7 | 169.1 | (126.3-221.8) |  |  |  |  |  |  |
| Female | 37 | 32.9 | 112.3 | (79.1-154.8) |  | Female | 7 | 11.1 | 63.2 | (25.3-130.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 13 | 7.6 | 171.7 | (91.3-293.6) |  | Male | 10 | 11.0 | 90.8 | (43.5-167.1) |
| Female | 1 | 2.2 | nc | (nc-nc) |  | Female | 10 | 12.0 | 83.2 | (39.9-153.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 79 | 91.9 | 85.9 | (68.0-107.1) |
| Female | 2 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 15 | 17.3 | 86.9 | (48.6-143.4) |  | Male | 5 | 6.9 | 72.2 | (23.3-168.4) |
| Female | 13 | 10.2 | 126.9 | (67.5-217.0) |  | Female | 5 | 4.6 | 108.4 | (34.9-253.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 4.4 | nc | (nc-nc) |  | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 12 | 12.2 | 98.6 | (50.9-172.3) |  | Male | 10 | 7.7 | 130.5 | (62.5-240.0) |
| Female | 13 | 9.4 | 139.0 | (73.9-237.7) |  | Female | 18 | 23.5 | 76.5 | (45.3-120.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 12 | 10.8 | 111.0 | (57.3-193.9) |  |  |  |  |  |  |
| Female | 4 | 3.9 | nc | (nc-nc) |  | Female | 27 | 28.8 | 93.7 | (61.7-136.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 54 | 51.6 | 104.6 | (78.6-136.5) |  | Male | 389 | 381.3 | 102.0 | (92.1-112.7) |
| Female | 82 | 60.1 | 136.4 | (108.5-169.3) |  | Female | 439 | 429.1 | 102.3 | (93.0-112.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

334

# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.1 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.1 | nc | (nc-nc) |
| Female | 4 | 7.1 | nc | (nc-nc) |  | Female | 2 | 0.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 6 | 7.1 | 84.5 | (30.9-184.0) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 3 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 3.9 | 179.9 | (72.1-370.7) |  | Male | 27 | 27.1 | 99.5 | (65.6-144.8) |
| Female | 0 | 3.4 | nc | (nc-nc) |  | Female | 15 | 23.0 | 65.1 | (36.4-107.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

335

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 8 | 3.1 | 257.5 | (110.9-507.3) |  | Male | 6 | 1.9 | 311.3 | (113.7-677.6) |
| Female | 1 | 1.6 | nc | (nc-nc) |  | Female | 3 | 2.2 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.6 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 4 | 1.7 | nc | (nc-nc) |
| Female | 20 | 18.4 | 108.8 | (66.4-168.1) |  | Female | 4 | 2.2 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 4 | 4.6 | nc | (nc-nc) |  | Female | 2 | 1.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 17 | 11.5 | 147.6 | (85.9-236.3) |
| Female | 1 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 1.9 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 0.5 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 1 | 2.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 3 | 4.7 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 2 | 5.9 | nc | (nc-nc) |  | Male | 63 | 41.6 | 151.4 | (116.3-193.7) |
| Female | 4 | 8.3 | nc | (nc-nc) |  | Female | 49 | 60.9 | 80.5 | (59.5-106.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

336

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 14 | 18.2 | 76.8 | (41.9-128.8) |  | Male | 14 | 12.2 | 114.9 | (62.8-192.8) |
| Female | 7 | 6.5 | 107.0 | (42.8-220.4) |  | Female | 9 | 9.7 | 92.8 | (42.3-176.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 3.7 | nc | (nc-nc) |  | Male | 4 | 3.9 | nc | (nc-nc) |
| Female | 6 | 3.2 | 188.6 | (68.9-410.4) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 8 | 10.8 | 73.9 | (31.8-145.7) |
| Female | 87 | 77.7 | 112.0 | (89.7-138.1) |  | Female | 5 | 9.2 | 54.1 | (17.4-126.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 9.2 | 98.0 | (44.7-186.0) |
| Female | 0 | 2.7 | nc | (nc-nc) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 16 | 20.1 | 79.6 | (45.5-129.3) |  |  |  |  |  |  |
| Female | 14 | 19.5 | 72.0 | (39.3-120.7) |  | Female | 5 | 6.5 | 76.6 | (24.7-178.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 4.7 | nc | (nc-nc) |  | Male | 8 | 6.9 | 116.8 | (50.3-230.1) |
| Female | 3 | 1.3 | nc | (nc-nc) |  | Female | 9 | 6.8 | 131.5 | (60.0-249.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 59 | 55.0 | 107.3 | (81.7-138.4) |
| Female | 3 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 5 | 11.2 | 44.8 | (14.4-104.6) |  | Male | 5 | 4.4 | 114.0 | (36.8-266.1) |
| Female | 3 | 6.1 | nc | (nc-nc) |  | Female | 3 | 2.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.7 | nc | (nc-nc) |  | Male | 5 | 3.1 | 158.9 | (51.2-370.7) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 7.6 | 131.6 | (63.0-242.1) |  | Male | 7 | 5.4 | 130.6 | (52.3-269.2) |
| Female | 10 | 5.6 | 179.6 | (86.0-330.3) |  | Female | 14 | 15.4 | 91.1 | (49.7-152.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 6.6 | 91.1 | (33.3-198.4) |  |  |  |  |  |  |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 22 | 16.8 | 130.8 | (82.0-198.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 18 | 31.9 | 56.4 | (33.4-89.1) |  | Male | 222 | 238.7 | 93.0 | (81.2-106.1) |
| Female | 32 | 34.0 | 94.1 | (64.3-132.8) |  | Female | 261 | 255.4 | 102.2 | (90.2-115.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

337

# Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 44 | 43.8 | 100.5 | (73.0-134.9) |  | Male | 20 | 27.7 | 72.2 | (44.1-111.5) |
| Female | 12 | 15.8 | 76.1 | (39.3-132.9) |  | Female | 19 | 21.5 | 88.2 | (53.1-137.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 8.4 | nc | (nc-nc) |  | Male | 10 | 9.0 | 111.3 | (53.3-204.8) |
| Female | 4 | 7.3 | nc | (nc-nc) |  | Female | 4 | 7.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 22 | 24.7 | 89.0 | (55.8-134.7) |
| Female | 196 | 174.8 | 112.1 | (97.0-129.0) |  | Female | 28 | 21.6 | 129.7 | (86.2-187.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 24 | 20.5 | 116.9 | (74.9-174.0) |
| Female | 8 | 5.5 | 145.8 | (62.8-287.4) |  | Female | 8 | 9.6 | 83.4 | (35.9-164.3) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 67 | 45.1 | 148.7 | (115.2-188.8) |  |  |  |  |  |  |
| Female | 50 | 44.6 | 112.1 | (83.2-147.8) |  | Female | 19 | 15.2 | 125.2 | (75.4-195.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 19 | 11.1 | 171.4 | (103.1-267.7) |  | Male | 13 | 16.1 | 80.6 | (42.9-137.9) |
| Female | 4 | 3.1 | nc | (nc-nc) |  | Female | 10 | 16.4 | 60.9 | (29.2-112.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 5 | 3.2 | 155.4 | (50.1-362.5) |  | Male | 125 | 132.4 | 94.4 | (78.6-112.4) |
| Female | 0 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 26 | 24.9 | 104.3 | (68.1-152.9) |  | Male | 12 | 10.2 | 117.6 | (60.7-205.4) |
| Female | 7 | 14.1 | 49.8 | (19.9-102.6) |  | Female | 11 | 6.3 | 174.7 | (87.1-312.7) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 6.4 | 78.0 | (25.1-182.0) |  | Male | 11 | 5.6 | 195.4 | (97.4-349.7) |
| Female | 4 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 17.8 | 101.2 | (60.0-160.0) |  | Male | 5 | 10.8 | 46.1 | (14.9-107.6) |
| Female | 9 | 12.8 | 70.4 | (32.1-133.6) |  | Female | 23 | 31.3 | 73.4 | (46.5-110.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 10 | 15.4 | 64.8 | (31.0-119.1) |  |  |  |  |  |  |
| Female | 4 | 5.3 | nc | (nc-nc) |  | Female | 34 | 40.2 | 84.5 | (58.5-118.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 86 | 76.7 | 112.1 | (89.7-138.5) |  | Male | 571 | 555.8 | 102.7 | (94.5-111.5) |
| Female | 81 | 83.1 | 97.5 | (77.5-121.2) |  | Female | 565 | 587.7 | 96.1 | (88.4-104.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

338

# Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 15 | 22.3 | 67.2 | (37.6-110.9) |  | Male | 14 | 15.5 | 90.6 | (49.5-152.0) |
| Female | 3 | 7.1 | nc | (nc-nc) |  | Female | 16 | 11.6 | 137.7 | (78.7-223.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 8 | 4.8 | 168.2 | (72.4-331.4) |  | Male | 8 | 5.0 | 161.6 | (69.6-318.4) |
| Female | 4 | 3.8 | nc | (nc-nc) |  | Female | 2 | 3.5 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 0.8 | nc | (nc-nc) |  | Male | 13 | 13.6 | 95.4 | (50.7-163.1) |
| Female | 114 | 97.9 | 116.4 | (96.0-139.8) |  | Female | 8 | 10.6 | 75.4 | (32.5-148.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 12.4 | 48.4 | (17.7-105.4) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 4 | 4.9 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 21 | 25.5 | 82.5 | (51.0-126.1) |  |  |  |  |  |  |
| Female | 37 | 21.5 | 171.9 | (121.0-236.9) |  | Female | 5 | 8.0 | 62.1 | (20.0-145.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 6.1 | nc | (nc-nc) |  | Male | 8 | 8.7 | 91.9 | (39.5-181.0) |
| Female | 2 | 1.4 | nc | (nc-nc) |  | Female | 5 | 7.2 | 69.0 | (22.2-161.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.8 | nc | (nc-nc) |  | Male | 92 | 74.7 | 123.2 | (99.3-151.1) |
| Female | 3 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 11 | 14.9 | 74.0 | (36.9-132.4) |  | Male | 7 | 5.5 | 126.4 | (50.6-260.4) |
| Female | 1 | 7.3 | nc | (nc-nc) |  | Female | 1 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 5 | 3.6 | 138.7 | (44.7-323.8) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 9.5 | 105.3 | (50.4-193.7) |  | Male | 10 | 7.0 | 142.9 | (68.4-262.8) |
| Female | 7 | 6.2 | 113.8 | (45.6-234.5) |  | Female | 17 | 19.8 | 85.9 | (50.0-137.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 8.7 | 57.4 | (18.5-133.9) |  |  |  |  |  |  |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 32 | 21.5 | 149.0 | (101.9-210.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 40.5 | 64.2 | (42.0-94.1) |  | Male | 295 | 307.2 | 96.0 | (85.4-107.6) |
| Female | 31 | 39.0 | 79.5 | (54.0-112.8) |  | Female | 317 | 304.9 | 104.0 | (92.8-116.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

339

# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 2 | 2.4 | nc | (nc-nc) |  | Male | 6 | 1.6 | 379.3 | (138.5-825.7) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 1 | 1.0 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 9 | 8.5 | 106.0 | (48.4-201.2) |  | Female | 0 | 1.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 0 | 2.6 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.9 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 8 | 8.1 | 98.5 | (42.4-194.1) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 4.4 | nc | (nc-nc) |  | Male | 25 | 32.0 | 78.0 | (50.5-115.2) |
| Female | 2 | 3.7 | nc | (nc-nc) |  | Female | 18 | 26.9 | 66.8 | (39.6-105.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

340

# Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 7 | 8.2 | 85.4 | (34.2-175.9) |  | Male | 6 | 5.5 | 109.5 | (40.0-238.4) |
| Female | 3 | 2.2 | nc | (nc-nc) |  | Female | 7 | 3.7 | 189.0 | (75.7-389.5) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) |  | Female | 1 | 1.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 6 | 4.9 | 123.3 | (45.0-268.4) |
| Female | 42 | 31.3 | 134.0 | (96.6-181.1) |  | Female | 1 | 3.4 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 3 | 1.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 4 | 9.1 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 7 | 6.5 | 108.0 | (43.3-222.6) |  | Female | 3 | 2.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 2.2 | nc | (nc-nc) |  | Male | 0 | 3.2 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 22 | 28.0 | 78.5 | (49.2-118.9) |
| Female | 1 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 5.2 | 154.0 | (66.3-303.5) |  | Male | 3 | 2.0 | nc | (nc-nc) |
| Female | 4 | 2.3 | nc | (nc-nc) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 2 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 3.4 | nc | (nc-nc) |  | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  | Female | 9 | 6.3 | 143.5 | (65.5-272.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 3.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 9 | 7.4 | 122.1 | (55.7-231.8) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 8 | 14.3 | 56.0 | (24.1-110.3) |  | Male | 88 | 111.2 | 79.1 | (63.5-97.5) |
| Female | 14 | 12.3 | 113.8 | (62.2-190.9) |  | Female | 112 | 97.0 | 115.5 | (95.1-138.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

341

# Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 15.4 | 110.3 | (64.2-176.6) |  | Male | 14 | 9.6 | 145.4 | (79.4-244.0) |
| Female | 1 | 5.1 | nc | (nc-nc) |  | Female | 7 | 6.9 | 101.0 | (40.4-208.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 2.7 | nc | (nc-nc) |  | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 0 | 2.3 | nc | (nc-nc) |  | Female | 4 | 2.4 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 12 | 8.4 | 142.2 | (73.4-248.3) |
| Female | 56 | 57.2 | 97.9 | (73.9-127.1) |  | Female | 3 | 6.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 7.1 | 98.8 | (39.6-203.6) |
| Female | 2 | 1.8 | nc | (nc-nc) |  | Female | 1 | 3.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 11 | 15.6 | 70.4 | (35.1-125.9) |  |  |  |  |  |  |
| Female | 11 | 14.6 | 75.3 | (37.5-134.7) |  | Female | 2 | 4.9 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 3.9 | nc | (nc-nc) |  | Male | 3 | 5.7 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 13 | 5.3 | 245.6 | (130.7-420.1) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 45 | 46.1 | 97.6 | (71.2-130.7) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 8.7 | 69.3 | (25.3-150.8) |  | Male | 1 | 3.6 | nc | (nc-nc) |
| Female | 0 | 4.6 | nc | (nc-nc) |  | Female | 0 | 2.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 2.2 | nc | (nc-nc) |  | Male | 2 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 5 | 6.0 | 83.3 | (26.8-194.3) |  | Male | 5 | 3.5 | 141.7 | (45.7-330.7) |
| Female | 5 | 4.1 | 120.6 | (38.9-281.4) |  | Female | 8 | 10.0 | 80.3 | (34.6-158.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 5 | 5.3 | 94.6 | (30.5-220.8) |  |  |  |  |  |  |
| Female | 1 | 1.7 | nc | (nc-nc) |  | Female | 9 | 12.8 | 70.1 | (32.0-133.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 27.2 | 58.8 | (33.6-95.5) |  | Male | 176 | 192.1 | 91.6 | (78.6-106.2) |
| Female | 11 | 26.6 | 41.4 | (20.6-74.0) |  | Female | 145 | 190.1 | 76.3 | (64.4-89.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

342

# Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 27 | 22.8 | 118.3 | (77.9-172.1) |  | Male | 13 | 13.8 | 94.0 | (50.0-160.8) |
| Female | 4 | 7.6 | nc | (nc-nc) |  | Female | 5 | 10.1 | 49.6 | (16.0-115.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.8 | nc | (nc-nc) |  | Male | 6 | 4.6 | 131.7 | (48.1-286.7) |
| Female | 2 | 3.2 | nc | (nc-nc) |  | Female | 5 | 3.6 | 139.8 | (45.1-326.3) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 15 | 12.3 | 122.3 | (68.4-201.8) |
| Female | 78 | 84.2 | 92.7 | (73.3-115.7) |  | Female | 16 | 10.3 | 155.0 | (88.5-251.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 9.9 | 71.0 | (28.4-146.2) |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 4 | 4.6 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 22.5 | 102.0 | (64.7-153.1) |  |  |  |  |  |  |
| Female | 21 | 21.2 | 98.9 | (61.2-151.2) |  | Female | 6 | 7.1 | 84.4 | (30.8-183.6) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 8 | 5.6 | 142.2 | (61.2-280.3) |  | Male | 12 | 8.2 | 145.8 | (75.3-254.8) |
| Female | 0 | 1.5 | nc | (nc-nc) |  | Female | 11 | 8.0 | 136.8 | (68.2-244.7) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 95 | 67.6 | 140.6 | (113.7-171.8) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 12.3 | 97.6 | (50.4-170.6) |  | Male | 5 | 5.2 | 96.0 | (30.9-224.0) |
| Female | 6 | 6.7 | 89.7 | (32.8-195.3) |  | Female | 2 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.2 | nc | (nc-nc) |  | Male | 5 | 2.2 | 226.8 | (73.1-529.3) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 8.6 | 81.2 | (32.5-167.3) |  | Male | 6 | 5.0 | 120.2 | (43.9-261.7) |
| Female | 5 | 5.8 | 85.9 | (27.7-200.4) |  | Female | 17 | 14.0 | 121.2 | (70.6-194.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 7.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 14 | 19.7 | 71.1 | (38.8-119.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 37 | 39.8 | 93.1 | (65.5-128.3) |  | Male | 312 | 279.0 | 111.8 | (99.8-125.0) |
| Female | 37 | 40.3 | 91.8 | (64.6-126.5) |  | Female | 259 | 280.4 | 92.4 | (81.5-104.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

343

# Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 18 | 22.5 | 79.9 | (47.3-126.3) |  | Male | 26 | 13.6 | 191.6 | (125.1-280.7) |
| Female | 6 | 7.8 | 77.2 | (28.2-168.0) |  | Female | 15 | 9.9 | 151.7 | (84.8-250.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 11 | 4.4 | 250.9 | (125.1-448.9) |
| Female | 4 | 3.2 | nc | (nc-nc) |  | Female | 6 | 3.5 | 170.7 | (62.3-371.6) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 0.7 | nc | (nc-nc) |  | Male | 8 | 12.0 | 66.5 | (28.6-131.0) |
| Female | 103 | 78.8 | 130.8 | (106.7-158.6) |  | Female | 5 | 10.2 | 49.0 | (15.8-114.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 9.5 | 73.4 | (29.4-151.3) |
| Female | 2 | 2.5 | nc | (nc-nc) |  | Female | 6 | 4.4 | 136.5 | (49.8-297.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 22.8 | 79.0 | (46.8-124.8) |  |  |  |  |  |  |
| Female | 15 | 22.7 | 65.9 | (36.9-108.8) |  | Female | 7 | 6.8 | 102.3 | (41.0-210.7) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 5.3 | nc | (nc-nc) |  | Male | 13 | 8.1 | 161.2 | (85.7-275.6) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 2 | 8.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 1.1 | nc | (nc-nc) |  | Male | 62 | 60.0 | 103.3 | (79.2-132.4) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 12 | 11.6 | 103.6 | (53.5-181.0) |  | Male | 0 | 5.1 | nc | (nc-nc) |
| Female | 6 | 6.4 | 94.0 | (34.3-204.5) |  | Female | 2 | 3.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.0 | nc | (nc-nc) |  | Male | 6 | 1.8 | 329.8 | (120.4-717.9) |
| Female | 1 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 10 | 8.4 | 119.6 | (57.2-219.9) |  | Male | 4 | 4.7 | nc | (nc-nc) |
| Female | 10 | 6.2 | 162.3 | (77.7-298.4) |  | Female | 20 | 13.4 | 149.6 | (91.3-231.0) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 7.3 | 96.4 | (38.6-198.6) |  |  |  |  |  |  |
| Female | 4 | 2.5 | nc | (nc-nc) |  | Female | 18 | 16.8 | 106.8 | (63.3-168.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 37.5 | 66.6 | (43.1-98.3) |  | Male | 259 | 265.3 | 97.6 | (86.1-110.2) |
| Female | 31 | 38.4 | 80.8 | (54.9-114.7) |  | Female | 283 | 271.7 | 104.2 | (92.4-117.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

344

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 68 | 59.9 | 113.5 | (88.1-143.9) |  | Male | 43 | 38.7 | 111.0 | (80.3-149.5) |
| Female | 37 | 25.1 | 147.3 | (103.7-203.0) |  | Female | 53 | 34.3 | 154.7 | (115.9-202.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 9 | 11.4 | 78.8 | (36.0-149.6) |  | Male | 12 | 12.4 | 97.0 | (50.1-169.5) |
| Female | 10 | 11.0 | 91.1 | (43.6-167.5) |  | Female | 6 | 11.8 | 51.0 | (18.6-110.9) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 2.1 | nc | (nc-nc) |  | Male | 40 | 34.2 | 116.9 | (83.5-159.2) |
| Female | 290 | 279.3 | 103.8 | (92.2-116.5) |  | Female | 29 | 34.4 | 84.3 | (56.4-121.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 27 | 28.4 | 94.9 | (62.5-138.1) |
| Female | 1 | 8.8 | nc | (nc-nc) |  | Female | 23 | 15.2 | 150.9 | (95.6-226.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 70 | 62.5 | 112.1 | (87.3-141.6) |  |  |  |  |  |  |
| Female | 68 | 70.3 | 96.7 | (75.1-122.6) |  | Female | 22 | 23.9 | 91.9 | (57.6-139.1) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 19 | 15.1 | 125.7 | (75.7-196.4) |  | Male | 18 | 22.2 | 81.2 | (48.1-128.3) |
| Female | 8 | 5.0 | 161.3 | (69.4-317.8) |  | Female | 22 | 26.1 | 84.1 | (52.7-127.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 6 | 4.5 | 133.9 | (48.9-291.5) |  | Male | 162 | 178.7 | 90.6 | (77.2-105.7) |
| Female | 2 | 4.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 36 | 34.7 | 103.7 | (72.6-143.5) |  | Male | 14 | 14.1 | 99.5 | (54.4-167.0) |
| Female | 28 | 22.4 | 125.2 | (83.2-180.9) |  | Female | 7 | 10.0 | 70.3 | (28.2-144.9) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 17 | 8.8 | 192.4 | (112.0-308.0) |  | Male | 10 | 8.5 | 117.6 | (56.3-216.4) |
| Female | 3 | 3.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 18 | 24.2 | 74.4 | (44.1-117.7) |  | Male | 14 | 15.6 | 89.6 | (48.9-150.4) |
| Female | 14 | 19.8 | 70.7 | (38.6-118.6) |  | Female | 44 | 49.4 | 89.0 | (64.7-119.5) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 20 | 21.2 | 94.5 | (57.7-145.9) |  |  |  |  |  |  |
| Female | 9 | 8.4 | 107.0 | (48.8-203.1) |  | Female | 71 | 64.9 | 109.5 | (85.5-138.1) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 134 | 106.1 | 126.3 | (105.9-149.6) |  | Male | 813 | 764.0 | 106.4 | (99.2-114.0) |
| Female | 154 | 133.1 | 115.7 | (98.2-135.5) |  | Female | 959 | 934.4 | 102.6 | (96.2-109.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

345

# Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 1.6 | nc | (nc-nc) |  | Male | 2 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 1 | 0.9 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.0 | nc | (nc-nc) |
| Female | 5 | 7.4 | 67.4 | (21.7-157.3) |  | Female | 0 | 0.9 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 3 | 1.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.5 | nc | (nc-nc) |  | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 7 | 6.2 | 113.5 | (45.5-233.8) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 1 | 1.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 2 | 1.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.9 | nc | (nc-nc) |  | Male | 25 | 22.7 | 110.4 | (71.4-162.9) |
| Female | 3 | 3.3 | nc | (nc-nc) |  | Female | 14 | 24.3 | 57.7 | (31.5-96.8) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

346

# Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 21 | 13.3 | 157.4 | (97.4-240.7) |  | Male | 11 | 9.2 | 119.6 | (59.6-214.0) |
| Female | 11 | 4.8 | 227.9 | (113.6-407.8) |  | Female | 14 | 7.5 | 186.1 | (101.7-312.3) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 2.9 | nc | (nc-nc) |  | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) |  | Female | 1 | 2.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 4 | 8.1 | nc | (nc-nc) |
| Female | 54 | 60.9 | 88.6 | (66.6-115.6) |  | Female | 4 | 7.0 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 9 | 7.2 | 124.4 | (56.8-236.2) |
| Female | 4 | 2.1 | nc | (nc-nc) |  | Female | 4 | 3.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 17 | 14.9 | 114.2 | (66.5-182.8) |  |  |  |  |  |  |
| Female | 15 | 14.2 | 105.9 | (59.2-174.6) |  | Female | 2 | 5.2 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.6 | 139.1 | (44.8-324.5) |  | Male | 3 | 5.2 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  | Female | 6 | 5.0 | 120.7 | (44.1-262.8) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 43 | 44.6 | 96.4 | (69.7-129.8) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 8.7 | 228.7 | (139.6-353.2) |  | Male | 3 | 3.3 | nc | (nc-nc) |
| Female | 3 | 4.7 | nc | (nc-nc) |  | Female | 1 | 2.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 2.1 | nc | (nc-nc) |  | Male | 2 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 7 | 5.7 | 122.4 | (49.0-252.1) |  | Male | 5 | 4.2 | 120.3 | (38.8-280.7) |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 13 | 12.2 | 106.3 | (56.6-181.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 5.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 6 | 13.9 | 43.2 | (15.8-93.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 24.3 | 106.8 | (69.8-156.5) |  | Male | 195 | 183.3 | 106.4 | (92.0-122.4) |
| Female | 43 | 26.0 | 165.2 | (119.5-222.5) |  | Female | 203 | 196.9 | 103.1 | (89.4-118.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

347

# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 17 | 22.3 | 76.2 | (44.4-122.1) |  | Male | 17 | 13.5 | 125.9 | (73.3-201.7) |
| Female | 11 | 7.0 | 157.1 | (78.3-281.1) |  | Female | 9 | 9.2 | 98.4 | (44.9-186.7) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 3.6 | nc | (nc-nc) |  | Male | 3 | 4.4 | nc | (nc-nc) |
| Female | 6 | 2.9 | 205.2 | (74.9-446.5) |  | Female | 3 | 3.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.7 | nc | (nc-nc) |  | Male | 8 | 11.9 | 67.3 | (29.0-132.6) |
| Female | 81 | 74.3 | 109.0 | (86.6-135.5) |  | Female | 10 | 9.3 | 107.9 | (51.6-198.4) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 9.9 | 111.6 | (55.6-199.7) |
| Female | 1 | 2.3 | nc | (nc-nc) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 22.4 | 80.4 | (47.6-127.0) |  |  |  |  |  |  |
| Female | 12 | 20.5 | 58.7 | (30.3-102.5) |  | Female | 10 | 6.4 | 157.0 | (75.2-288.8) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 5.4 | nc | (nc-nc) |  | Male | 2 | 8.1 | nc | (nc-nc) |
| Female | 3 | 1.4 | nc | (nc-nc) |  | Female | 9 | 7.5 | 120.2 | (54.9-228.2) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 1.2 | nc | (nc-nc) |  | Male | 45 | 65.8 | 68.4 | (49.9-91.6) |
| Female | 0 | 0.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 11.9 | 75.3 | (34.4-143.0) |  | Male | 3 | 5.1 | nc | (nc-nc) |
| Female | 4 | 5.9 | nc | (nc-nc) |  | Female | 3 | 2.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 3.1 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 8.3 | nc | (nc-nc) |  | Male | 5 | 4.7 | 106.2 | (34.2-247.9) |
| Female | 6 | 5.6 | 107.8 | (39.4-234.7) |  | Female | 10 | 12.6 | 79.3 | (38.0-145.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 7.4 | 80.8 | (29.5-175.9) |  |  |  |  |  |  |
| Female | 2 | 2.2 | nc | (nc-nc) |  | Female | 10 | 16.4 | 61.1 | (29.3-112.4) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 26 | 38.4 | 67.8 | (44.3-99.3) |  | Male | 204 | 271.5 | 75.1 | (65.2-86.2) |
| Female | 27 | 35.2 | 76.7 | (50.5-111.6) |  | Female | 238 | 251.6 | 94.6 | (82.9-107.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

348

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 3.4 | nc | (nc-nc) |  | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 0.6 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 19 | 14.4 | 132.2 | (79.5-206.4) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 1 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 0.8 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 2 | 3.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 3.6 | nc | (nc-nc) |  | Female | 3 | 1.3 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 0.9 | nc | (nc-nc) |  | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 1.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 5 | 11.3 | 44.3 | (14.3-103.4) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 4 | 2.0 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 2 | 1.1 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) |  | Female | 2 | 2.3 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 1.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 5 | 3.5 | 144.1 | (46.4-336.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 4 | 6.3 | nc | (nc-nc) |  | Male | 28 | 44.3 | 63.2 | (42.0-91.3) |
| Female | 3 | 6.7 | nc | (nc-nc) |  | Female | 45 | 47.4 | 94.9 | (69.2-127.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

349

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 9.9 | 91.3 | (41.7-173.3) |  | Male | 7 | 5.6 | 125.1 | (50.1-257.7) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 2 | 4.3 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) |  | Female | 1 | 1.7 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 7 | 5.0 | 139.8 | (56.0-288.1) |
| Female | 21 | 33.7 | 62.4 | (38.6-95.4) |  | Female | 3 | 4.8 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 2 | 3.7 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) |  | Female | 1 | 2.1 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 9.3 | 64.8 | (23.7-141.1) |  |  |  |  |  |  |
| Female | 6 | 10.5 | 56.9 | (20.8-123.9) |  | Female | 2 | 3.1 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 2.2 | nc | (nc-nc) |  | Male | 3 | 3.4 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 3 | 4.1 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  | Male | 21 | 25.1 | 83.8 | (51.8-128.1) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 6 | 4.5 | 131.9 | (48.2-287.2) |  | Male | 3 | 2.1 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 0 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 1 | 1.2 | nc | (nc-nc) |  | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 0 | 3.7 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 3 | 4.9 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 1 | 3.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 3 | 1.2 | nc | (nc-nc) |  | Female | 4 | 7.8 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 5 | 16.2 | 30.8 | (9.9-72.0) |  | Male | 83 | 111.0 | 74.8 | (59.6-92.7) |
| Female | 16 | 18.8 | 85.1 | (48.6-138.1) |  | Female | 83 | 123.8 | 67.1 | (53.4-83.1) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

350

# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 24 | 23.9 | 100.5 | (64.4-149.5) |  | Male | 12 | 15.4 | 77.8 | (40.2-136.0) |
| Female | 6 | 8.6 | 70.0 | (25.6-152.3) |  | Female | 12 | 12.6 | 95.4 | (49.2-166.6) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 5 | 4.6 | 107.9 | (34.8-251.8) |  | Male | 4 | 4.9 | nc | (nc-nc) |
| Female | 5 | 4.1 | 122.9 | (39.6-286.7) |  | Female | 4 | 4.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 10 | 13.8 | 72.5 | (34.7-133.4) |
| Female | 121 | 101.9 | 118.7 | (98.5-141.9) |  | Female | 17 | 12.1 | 140.1 | (81.6-224.3) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 12 | 11.6 | 103.5 | (53.4-180.8) |
| Female | 3 | 3.4 | nc | (nc-nc) |  | Female | 4 | 5.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 23 | 25.6 | 89.7 | (56.8-134.6) |  |  |  |  |  |  |
| Female | 29 | 25.3 | 114.6 | (76.8-164.7) |  | Female | 6 | 8.7 | 69.1 | (25.2-150.3) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 3 | 6.0 | nc | (nc-nc) |  | Male | 8 | 8.9 | 89.9 | (38.7-177.1) |
| Female | 0 | 1.7 | nc | (nc-nc) |  | Female | 7 | 9.0 | 77.9 | (31.2-160.6) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 48 | 72.8 | 66.0 | (48.6-87.4) |
| Female | 2 | 1.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 14.1 | 141.9 | (86.7-219.2) |  | Male | 2 | 5.6 | nc | (nc-nc) |
| Female | 5 | 8.0 | 62.8 | (20.2-146.6) |  | Female | 5 | 3.5 | 140.9 | (45.4-328.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 3.5 | nc | (nc-nc) |  | Male | 2 | 3.4 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 9.8 | 143.3 | (78.3-240.4) |  | Male | 8 | 6.4 | 124.4 | (53.6-245.1) |
| Female | 5 | 7.1 | 70.0 | (22.5-163.3) |  | Female | 14 | 19.4 | 72.3 | (39.5-121.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 8.5 | 82.5 | (33.0-169.9) |  |  |  |  |  |  |
| Female | 2 | 2.9 | nc | (nc-nc) |  | Female | 20 | 23.0 | 86.9 | (53.1-134.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 43 | 41.1 | 104.6 | (75.7-140.9) |  | Male | 270 | 307.1 | 87.9 | (77.7-99.1) |
| Female | 45 | 44.8 | 100.5 | (73.3-134.5) |  | Female | 340 | 334.5 | 101.6 | (91.1-113.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

351

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 9 | 11.9 | 75.6 | (34.5-143.5) |  | Male | 1 | 7.7 | nc | (nc-nc) |
| Female | 3 | 3.8 | nc | (nc-nc) |  | Female | 3 | 5.7 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 1 | 2.3 | nc | (nc-nc) |  | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) |  | Female | 1 | 1.8 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 5 | 6.8 | 73.9 | (23.8-172.3) |
| Female | 35 | 47.3 | 74.0 | (51.5-102.9) |  | Female | 1 | 5.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 11 | 5.7 | 194.6 | (97.0-348.2) |
| Female | 3 | 1.5 | nc | (nc-nc) |  | Female | 0 | 2.5 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 10 | 12.6 | 79.4 | (38.0-146.1) |  |  |  |  |  |  |
| Female | 16 | 11.1 | 144.4 | (82.5-234.6) |  | Female | 4 | 4.0 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 5 | 3.0 | 167.3 | (53.9-390.5) |  | Male | 9 | 4.4 | 204.5 | (93.3-388.2) |
| Female | 1 | 0.7 | nc | (nc-nc) |  | Female | 4 | 3.9 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.9 | nc | (nc-nc) |  | Male | 19 | 35.1 | 54.1 | (32.5-84.4) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 6.9 | 116.6 | (50.2-229.7) |  | Male | 1 | 2.8 | nc | (nc-nc) |
| Female | 8 | 3.7 | 217.2 | (93.5-428.0) |  | Female | 2 | 1.5 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 1.8 | nc | (nc-nc) |  | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.8 | nc | (nc-nc) |  | Male | 1 | 3.1 | nc | (nc-nc) |
| Female | 1 | 3.1 | nc | (nc-nc) |  | Female | 6 | 8.7 | 69.0 | (25.2-150.1) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 3 | 4.2 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.3 | nc | (nc-nc) |  | Female | 7 | 10.8 | 64.7 | (25.9-133.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 16 | 20.8 | 76.8 | (43.8-124.7) |  | Male | 123 | 151.2 | 81.4 | (67.6-97.1) |
| Female | 21 | 20.9 | 100.5 | (62.2-153.7) |  | Female | 129 | 152.2 | 84.7 | (70.7-100.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

352

# Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 20 | 24.8 | 80.7 | (49.3-124.6) |  | Male | 16 | 16.0 | 100.0 | (57.1-162.3) |
| Female | 8 | 9.3 | 86.0 | (37.0-169.4) |  | Female | 13 | 13.0 | 100.1 | (53.3-171.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 6 | 4.6 | 129.8 | (47.4-282.5) |  | Male | 6 | 5.1 | 117.6 | (42.9-256.0) |
| Female | 4 | 4.2 | nc | (nc-nc) |  | Female | 4 | 4.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.9 | nc | (nc-nc) |  | Male | 15 | 14.1 | 106.2 | (59.4-175.2) |
| Female | 116 | 106.2 | 109.3 | (90.3-131.1) |  | Female | 14 | 12.8 | 109.7 | (60.0-184.2) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 7 | 11.6 | 60.3 | (24.1-124.2) |
| Female | 2 | 3.6 | nc | (nc-nc) |  | Female | 7 | 5.7 | 123.4 | (49.4-254.2) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 26 | 26.1 | 99.7 | (65.1-146.1) |  |  |  |  |  |  |
| Female | 25 | 27.1 | 92.4 | (59.8-136.4) |  | Female | 9 | 8.9 | 101.1 | (46.1-192.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 2 | 6.1 | nc | (nc-nc) |  | Male | 8 | 9.2 | 87.2 | (37.5-171.8) |
| Female | 0 | 1.8 | nc | (nc-nc) |  | Female | 9 | 9.8 | 91.4 | (41.7-173.5) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.6 | nc | (nc-nc) |  | Male | 73 | 71.3 | 102.4 | (80.2-128.7) |
| Female | 0 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 9 | 14.4 | 62.7 | (28.6-119.0) |  | Male | 4 | 5.8 | nc | (nc-nc) |
| Female | 16 | 8.4 | 191.4 | (109.3-310.8) |  | Female | 2 | 3.8 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 3.6 | nc | (nc-nc) |  | Male | 0 | 3.1 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 16 | 10.0 | 160.5 | (91.7-260.6) |  | Male | 7 | 6.4 | 108.6 | (43.5-223.8) |
| Female | 8 | 7.6 | 105.3 | (45.3-207.5) |  | Female | 20 | 19.5 | 102.4 | (62.5-158.2) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 6 | 8.5 | 70.9 | (25.9-154.4) |  |  |  |  |  |  |
| Female | 2 | 3.0 | nc | (nc-nc) |  | Female | 26 | 23.2 | 111.8 | (73.0-163.9) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 25 | 43.4 | 57.5 | (37.2-84.9) |  | Male | 277 | 311.8 | 88.8 | (78.7-99.9) |
| Female | 38 | 48.5 | 78.3 | (55.4-107.5) |  | Female | 356 | 351.6 | 101.2 | (91.0-112.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

353

# Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 0 | 1.3 | nc | (nc-nc) |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 3 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.0 | nc | (nc-nc) |  | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 5 | 4.5 | 111.6 | (36.0-260.3) |  | Female | 0 | 0.5 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 6 | 1.4 | 414.9 | (151.5-903.1) |  |  |  |  |  |  |
| Female | 2 | 0.9 | nc | (nc-nc) |  | Female | 1 | 0.4 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.3 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 0 | 4.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 0 | 0.8 | nc | (nc-nc) |  | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) |  | Female | 0 | 0.1 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.2 | nc | (nc-nc) |  | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 2 | 1.1 | nc | (nc-nc) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 1 | 2.4 | nc | (nc-nc) |  | Male | 15 | 18.0 | 83.3 | (46.6-137.4) |
| Female | 3 | 1.8 | nc | (nc-nc) |  | Female | 19 | 13.7 | 138.3 | (83.2-216.0) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

354

# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 19 | 22.4 | 84.9 | (51.1-132.6) |  | Male | 25 | 14.2 | 176.0 | (113.9-259.9) |
| Female | 10 | 7.6 | 130.9 | (62.7-240.8) |  | Female | 24 | 10.8 | 223.2 | (143.0-332.2) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 4.1 | nc | (nc-nc) |  | Male | 7 | 4.6 | 151.0 | (60.5-311.2) |
| Female | 3 | 3.5 | nc | (nc-nc) |  | Female | 3 | 3.6 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 9 | 12.5 | 71.9 | (32.8-136.4) |
| Female | 84 | 88.1 | 95.4 | (76.1-118.1) |  | Female | 6 | 10.6 | 56.5 | (20.6-123.0) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 6 | 10.5 | 57.1 | (20.8-124.2) |
| Female | 2 | 2.8 | nc | (nc-nc) |  | Female | 5 | 4.7 | 106.2 | (34.2-247.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 29 | 22.7 | 127.9 | (85.6-183.7) |  |  |  |  |  |  |
| Female | 26 | 21.6 | 120.3 | (78.5-176.2) |  | Female | 5 | 7.6 | 66.2 | (21.3-154.5) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 9 | 5.7 | 157.3 | (71.8-298.7) |  | Male | 16 | 8.3 | 193.1 | (110.3-313.7) |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 5 | 7.8 | 63.8 | (20.6-149.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 1.5 | nc | (nc-nc) |  | Male | 66 | 69.0 | 95.7 | (74.0-121.7) |
| Female | 2 | 1.4 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 20 | 12.8 | 156.6 | (95.6-241.9) |  | Male | 7 | 5.2 | 134.4 | (53.8-276.9) |
| Female | 8 | 7.0 | 114.0 | (49.1-224.7) |  | Female | 4 | 3.0 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 2 | 3.3 | nc | (nc-nc) |  | Male | 2 | 2.7 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 3 | 8.8 | nc | (nc-nc) |  | Male | 9 | 5.4 | 167.3 | (76.4-317.6) |
| Female | 9 | 6.1 | 146.5 | (66.9-278.2) |  | Female | 9 | 16.2 | 55.5 | (25.3-105.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 7 | 8.0 | 87.4 | (35.0-180.2) |  |  |  |  |  |  |
| Female | 2 | 2.6 | nc | (nc-nc) |  | Female | 23 | 20.1 | 114.3 | (72.4-171.5) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 54 | 40.1 | 134.8 | (101.3-175.9) |  | Male | 316 | 284.6 | 111.0 | (99.1-124.0) |
| Female | 56 | 41.1 | 136.1 | (102.8-176.8) |  | Female | 307 | 291.3 | 105.4 | (93.9-117.9) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

355

# Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 53 | 43.7 | 121.4 | (90.9-158.8) |  | Male | 31 | 27.7 | 111.9 | (76.0-158.8) |
| Female | 23 | 15.6 | 147.1 | (93.2-220.7) |  | Female | 14 | 21.4 | 65.5 | (35.8-110.0) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 4 | 8.2 | nc | (nc-nc) |  | Male | 10 | 8.7 | 114.4 | (54.8-210.5) |
| Female | 9 | 6.9 | 130.5 | (59.5-247.7) |  | Female | 6 | 7.2 | 83.4 | (30.5-181.5) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 2 | 1.5 | nc | (nc-nc) |  | Male | 34 | 24.5 | 138.6 | (96.0-193.7) |
| Female | 208 | 166.2 | 125.2 | (108.7-143.4) |  | Female | 29 | 21.2 | 136.9 | (91.7-196.7) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 19.9 | 75.3 | (42.1-124.3) |
| Female | 11 | 5.4 | 202.8 | (101.1-362.9) |  | Female | 6 | 9.2 | 65.0 | (23.7-141.4) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 56 | 45.0 | 124.3 | (93.9-161.4) |  |  |  |  |  |  |
| Female | 53 | 44.8 | 118.3 | (88.6-154.7) |  | Female | 13 | 14.6 | 89.0 | (47.3-152.2) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 11 | 10.7 | 103.1 | (51.4-184.5) |  | Male | 10 | 15.9 | 63.0 | (30.2-115.8) |
| Female | 0 | 3.0 | nc | (nc-nc) |  | Female | 15 | 16.3 | 91.8 | (51.3-151.3) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 2 | 3.4 | nc | (nc-nc) |  | Male | 108 | 124.6 | 86.6 | (71.1-104.6) |
| Female | 2 | 2.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 27 | 24.3 | 111.2 | (73.3-161.8) |  | Male | 11 | 10.1 | 108.9 | (54.3-194.9) |
| Female | 13 | 13.5 | 96.2 | (51.2-164.5) |  | Female | 7 | 6.3 | 110.9 | (44.4-228.5) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 4 | 6.1 | nc | (nc-nc) |  | Male | 7 | 6.7 | 104.1 | (41.7-214.4) |
| Female | 4 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 14 | 17.6 | 79.6 | (43.5-133.6) |  | Male | 13 | 11.1 | 117.0 | (62.3-200.2) |
| Female | 12 | 12.7 | 94.3 | (48.6-164.7) |  | Female | 38 | 31.0 | 122.7 | (86.8-168.4) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 18 | 14.9 | 121.1 | (71.7-191.4) |  |  |  |  |  |  |
| Female | 2 | 5.2 | nc | (nc-nc) |  | Female | 29 | 37.4 | 77.4 | (51.9-111.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 101 | 75.2 | 134.4 | (109.4-163.3) |  | Male | 588 | 544.3 | 108.0 | (99.5-117.1) |
| Female | 88 | 80.0 | 109.9 | (88.2-135.4) |  | Female | 634 | 569.7 | 111.3 | (102.8-120.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

356

# Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 167 | 163.7 | 102.0 | (87.1-118.7) |  | Male | 73 | 106.2 | 68.7 | (53.9-86.4) |
| Female | 60 | 62.8 | 95.5 | (72.9-123.0) |  | Female | 68 | 88.8 | 76.6 | (59.5-97.1) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 31 | 33.6 | 92.2 | (62.6-130.8) |  | Male | 29 | 33.5 | 86.6 | (58.0-124.3) |
| Female | 22 | 30.2 | 72.9 | (45.7-110.4) |  | Female | 25 | 29.0 | 86.1 | (55.7-127.1) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 3 | 5.7 | nc | (nc-nc) |  | Male | 96 | 95.2 | 100.9 | (81.7-123.2) |
| Female | 634 | 692.0 | 91.6 | (84.6-99.0) |  | Female | 65 | 86.2 | 75.4 | (58.2-96.1) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 69 | 78.3 | 88.2 | (68.6-111.6) |
| Female | 31 | 23.2 | 133.4 | (90.6-189.4) |  | Female | 47 | 38.1 | 123.2 | (90.5-163.9) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 164 | 174.3 | 94.1 | (80.2-109.6) |  |  |  |  |  |  |
| Female | 159 | 181.8 | 87.4 | (74.4-102.1) |  | Female | 52 | 60.7 | 85.7 | (64.0-112.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 56 | 40.9 | 137.1 | (103.5-178.0) |  | Male | 66 | 60.4 | 109.3 | (84.5-139.0) |
| Female | 16 | 12.1 | 132.0 | (75.4-214.4) |  | Female | 70 | 65.8 | 106.3 | (82.9-134.4) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 13 | 14.6 | 88.9 | (47.3-152.1) |  | Male | 424 | 477.3 | 88.8 | (80.6-97.7) |
| Female | 18 | 13.1 | 137.2 | (81.2-216.8) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 97 | 94.7 | 102.5 | (83.1-125.0) |  | Male | 39 | 38.5 | 101.4 | (72.1-138.6) |
| Female | 66 | 55.9 | 118.1 | (91.4-150.3) |  | Female | 20 | 25.5 | 78.4 | (47.9-121.1) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 22 | 23.6 | 93.3 | (58.5-141.3) |  | Male | 22 | 28.3 | 77.7 | (48.7-117.7) |
| Female | 12 | 7.7 | 156.2 | (80.6-272.8) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 70 | 69.3 | 101.0 | (78.7-127.6) |  | Male | 43 | 45.0 | 95.5 | (69.1-128.7) |
| Female | 57 | 52.9 | 107.7 | (81.5-139.5) |  | Female | 136 | 135.2 | 100.6 | (84.4-118.9) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 75 | 57.6 | 130.2 | (102.4-163.2) |  |  |  |  |  |  |
| Female | 27 | 20.8 | 129.6 | (85.4-188.5) |  | Female | 176 | 154.3 | 114.0 | (97.8-132.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 329 | 280.3 | 117.4 | (105.0-130.8) |  | Male | 2052 | 2092.8 | 98.0 | (93.9-102.4) |
| Female | 347 | 325.0 | 106.8 | (95.8-118.6) |  | Female | 2313 | 2353.6 | 98.3 | (94.3-102.4) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

357

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) |  | Female | 1 | 0.8 | nc | (nc-nc) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 2 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.3 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 0.1 | nc | (nc-nc) |  | Male | 3 | 1.1 | nc | (nc-nc) |
| Female | 8 | 6.6 | 121.3 | (52.2-238.9) |  | Female | 1 | 0.7 | nc | (nc-nc) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 0 | 0.4 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 1 | 2.0 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 1 | 1.5 | nc | (nc-nc) |  | Female | 0 | 0.6 | nc | (nc-nc) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 1 | 0.5 | nc | (nc-nc) |  | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  | Female | 1 | 0.5 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 0 | 0.1 | nc | (nc-nc) |  | Male | 1 | 6.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 1 | 1.1 | nc | (nc-nc) |  | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) |  | Female | 0 | 0.2 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 0.3 | nc | (nc-nc) |  | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) |  | Female | 0 | 1.1 | nc | (nc-nc) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 2 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 0 | 0.2 | nc | (nc-nc) |  | Female | 6 | 1.6 | 371.8 | (135.8-809.3) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 7 | 3.4 | 208.2 | (83.4-429.1) |  | Male | 23 | 24.4 | 94.1 | (59.6-141.2) |
| Female | 0 | 2.8 | nc | (nc-nc) |  | Female | 23 | 21.1 | 109.1 | (69.1-163.6) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

358

# Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 12 | 10.3 | 116.2 | (60.0-202.9) |  | Male | 9 | 7.2 | 124.4 | (56.8-236.1) |
| Female | 3 | 4.5 | nc | (nc-nc) |  | Female | 11 | 6.4 | 173.2 | (86.3-309.8) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 0 | 2.3 | nc | (nc-nc) |  | Male | 0 | 2.3 | nc | (nc-nc) |
| Female | 2 | 2.0 | nc | (nc-nc) |  | Female | 2 | 2.1 | nc | (nc-nc) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 0 | 0.4 | nc | (nc-nc) |  | Male | 13 | 6.4 | 203.8 | (108.4-348.6) |
| Female | 62 | 51.5 | 120.4 | (92.3-154.4) |  | Female | 6 | 6.3 | 95.8 | (35.0-208.6) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 4 | 5.9 | nc | (nc-nc) |
| Female | 2 | 1.7 | nc | (nc-nc) |  | Female | 4 | 2.7 | nc | (nc-nc) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 18 | 12.1 | 148.6 | (88.1-234.9) |  |  |  |  |  |  |
| Female | 13 | 13.3 | 98.1 | (52.2-167.8) |  | Female | 9 | 4.4 | 204.4 | (93.3-388.0) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 4 | 2.8 | nc | (nc-nc) |  | Male | 7 | 4.1 | 172.2 | (69.0-354.9) |
| Female | 0 | 0.8 | nc | (nc-nc) |  | Female | 3 | 4.6 | nc | (nc-nc) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 1 | 0.8 | nc | (nc-nc) |  | Male | 56 | 34.7 | 161.5 | (122.0-209.8) |
| Female | 0 | 0.7 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 8 | 6.9 | 115.6 | (49.8-227.7) |  | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 5 | 4.0 | 123.6 | (39.8-288.4) |  | Female | 2 | 1.9 | nc | (nc-nc) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 0 | 1.7 | nc | (nc-nc) |  | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 4 | 4.5 | nc | (nc-nc) |  | Male | 8 | 3.2 | 246.8 | (106.3-486.3) |
| Female | 3 | 3.7 | nc | (nc-nc) |  | Female | 9 | 9.5 | 94.7 | (43.2-179.8) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 4 | 4.3 | nc | (nc-nc) |  |  |  |  |  |  |
| Female | 2 | 1.5 | nc | (nc-nc) |  | Female | 6 | 11.2 | 53.4 | (19.5-116.2) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 17 | 18.6 | 91.6 | (53.3-146.6) |  | Male | 184 | 143.5 | 128.2 | (110.3-148.1) |
| Female | 15 | 22.9 | 65.5 | (36.6-108.1) |  | Female | 170 | 169.8 | 100.1 | (85.6-116.3) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

359

# Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Obs** | **Exp** | **SIR** | **95% CI** |  |  | **Obs** | **Exp** | **SIR** | **95% CI** |
| **Bladder, Urinary** | | | |  |  | **Melanoma of Skin** | | |  |  |
| Male | 50 | 47.0 | 106.5 | (79.0-140.4) |  | Male | 52 | 26.1 | 199.0 | (148.6-261.0) |
| Female | 22 | 17.4 | 126.1 | (79.0-190.9) |  | Female | 43 | 19.2 | 224.5 | (162.4-302.4) |
| **Brain and Other Nervous System** | | | |  |  | **Multiple Myeloma** | | |  |  |
| Male | 7 | 6.3 | 111.1 | (44.5-228.8) |  | Male | 9 | 8.5 | 105.7 | (48.2-200.7) |
| Female | 6 | 6.1 | 98.3 | (35.9-213.9) |  | Female | 6 | 7.6 | 78.7 | (28.7-171.2) |
| **Breast** | | | |  |  | **Non-Hodgkin Lymphoma** | | |  |  |
| Male | 1 | 1.5 | nc | (nc-nc) |  | Male | 21 | 23.1 | 90.9 | (56.3-139.0) |
| Female | 181 | 154.6 | 117.1 | (100.6-135.4) |  | Female | 24 | 21.6 | 111.2 | (71.2-165.5) |
| **Cervix Uteri** | | | |  |  | **Oral Cavity & Pharynx** | | |  |  |
|  |  |  |  |  |  | Male | 15 | 16.1 | 93.0 | (52.0-153.5) |
| Female | 1 | 4.1 | nc | (nc-nc) |  | Female | 17 | 9.1 | 186.2 | (108.4-298.1) |
| **Colon / Rectum** | | | |  |  | **Ovary** | | |  |  |
| Male | 37 | 43.3 | 85.4 | (60.1-117.7) |  |  |  |  |  |  |
| Female | 39 | 46.5 | 83.9 | (59.7-114.7) |  | Female | 9 | 13.7 | 65.5 | (29.9-124.4) |
| **Esophagus** | | | |  |  | **Pancreas** | | |  |  |
| Male | 19 | 10.1 | 188.5 | (113.4-294.4) |  | Male | 19 | 15.8 | 120.0 | (72.2-187.5) |
| Female | 8 | 3.3 | 243.3 | (104.8-479.4) |  | Female | 22 | 18.3 | 120.2 | (75.3-182.0) |
| **Hodgkin Lymphoma** | | | |  |  | **Prostate** | | |  |  |
| Male | 3 | 2.0 | nc | (nc-nc) |  | Male | 137 | 107.0 | 128.0 | (107.5-151.4) |
| Female | 3 | 1.8 | nc | (nc-nc) |  |  |  |  |  |  |
| **Kidney & Renal Pelvis** | | | |  |  | **Stomach** | | |  |  |
| Male | 17 | 20.3 | 83.6 | (48.7-133.9) |  | Male | 6 | 10.0 | 59.8 | (21.8-130.2) |
| Female | 11 | 13.3 | 82.4 | (41.1-147.5) |  | Female | 6 | 6.6 | 91.3 | (33.4-198.8) |
| **Larynx** | | | |  |  | **Testis** | | |  |  |
| Male | 3 | 5.6 | nc | (nc-nc) |  | Male | 2 | 3.1 | nc | (nc-nc) |
| Female | 2 | 1.9 | nc | (nc-nc) |  |  |  |  |  |  |
| **Leukemia** | | | |  |  | **Thyroid** | | |  |  |
| Male | 32 | 16.3 | 196.4 | (134.3-277.3) |  | Male | 8 | 7.4 | 108.0 | (46.5-212.8) |
| Female | 22 | 12.6 | 175.0 | (109.6-264.9) |  | Female | 12 | 21.4 | 56.0 | (28.9-97.7) |
| **Liver and Intrahepatic Bile Ducts** | | | |  |  | **Uteri Corpus and Uterus, NOS** | | |  |  |
| Male | 21 | 13.0 | 161.8 | (100.1-247.4) |  |  |  |  |  |  |
| Female | 9 | 5.3 | 169.7 | (77.4-322.1) |  | Female | 28 | 35.5 | 78.8 | (52.4-114.0) |
| **Lung and Bronchus** | | | |  |  | **All Sites / Types** | | |  |  |
| Male | 73 | 76.1 | 95.9 | (75.2-120.6) |  | Male | 573 | 503.7 | 113.8 | (104.6-123.5) |
| Female | 98 | 89.2 | 109.9 | (89.2-133.9) |  | Female | 623 | 558.3 | 111.6 | (103.0-120.7) |

          Obs = observed case count; Exp = expected case count;

          SIR = standardized incidence ratio ( (Obs / Exp) X 100);

          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

          Shading indicates the statistical significance of the SIR at 95% level of probability;

          nc = The SIR and 95% CI were not calculated when Obs < 5;

360